Drug profile

The FDA adverse-event record for Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live

18 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live. See the species affected, top reactions, and outcomes below.

18
adverse-event reports
33.3%
death-coded share
Dog
most-reported species
7
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
6
Deaths Reported
33.3%
Death Rate

Active Ingredients

Canine Adenovirus Type 2,Toronto A/26/61,LiveCanine Coronavirus,K-378/51,LiveCanine Distemper,Vcp258,VectorCanine Parainfluenza Virus,D-008,LiveCanine Parvovirus,780916,Live

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 18

Most Affected Breeds

Retriever - Labrador 6
Crossbred Canine/dog 1
Boxer (German Boxer) 1
Rottweiler 1
Dog (unknown) 1
Poodle - Toy 1
Bulldog - French 1
Collie - Border 1
Doberman Pinscher 1
Chihuahua 1

Most Reported Reactions

Vomiting 7
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 6
Death 5
Lethargy (see also Central nervous system depression in 'Neurological') 3
Anaemia NOS 3
Not eating 3
Proprioception deficit 2
Leucocytosis NOS 2
Neutrophilia 2
Fever 2
Elevated serum alkaline phosphatase (ALP) 2
Low blood urea nitrogen (BUN) 2

Outcome Breakdown

Recovered/Normal
7 (36.8%)
Died
5 (26.3%)
Outcome Unknown
4 (21.1%)
Ongoing
2 (10.5%)
Euthanized
1 (5.3%)

Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live Adverse Event Insights

18 reports name Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live; 6 recorded a death outcome (33.3% of reported events, not a population-level mortality rate). Active ingredients: Canine Adenovirus Type 2,Toronto A/26/61,Live, Canine Coronavirus,K-378/51,Live, Canine Distemper,Vcp258,Vector, Canine Parainfluenza Virus,D-008,Live, Canine Parvovirus,780916,Live. Administration routes: Subcutaneous, Unknown.

By species: Dog (18 reports). By breed: Retriever - Labrador (6), Crossbred Canine/dog (1), Boxer (German Boxer) (1).

Leading clinical signs: Vomiting (7), Lack of efficacy (virus) - parvovirus (including feline panleukopenia) (6), Death (5), Lethargy (see also Central nervous system depression in 'Neurological') (3). Outcome, 19 coded reports: Recovered/Normal leads at 36.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.